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ABSTRACT
Several Campylobacter jejuni heat-stable (HS) ser-
otypes have been associated with the autoim-
mune Guillain–Barre´ neurological syndrome
(GBS). In order to examine the possible involve-
ment of cytokines in this phenomenon, the levels
of three pro-inﬂammatory cytokines (interleukin
(IL)-2sRa, IL-6 and interferon (IFN)-c) and one
anti-inﬂammatory cytokine (IL-10) were meas-
ured in peripheral blood mononuclear cells after
induction by different C. jejuni serotypes. No
differences were found for IL-6, IFN-c and IL-10,
but the non-sialylated serotype HS:3 was associ-
ated with decreased production of IL-2sRa. The
results raise the possibility that absence of sialy-
lation might be associated with the inability to
induce inﬂammatory factors such as cytokines.
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Guillain–Barre´ Syndrome (GBS) may result from
the production of antibodies to Campylobacter
jejuni polysaccharides, which then cross-react with
gangliosides of the peripheral nerves [1]. In addi-
tion, T-lymphocyte subsets, monocytes and cytok-
ines can trigger immune-mediated inﬂammatory
responses that cause demyelination [2,3]. Certain
pro- and anti-inﬂammatory cytokines have been
found in the peripheral blood of GBS patients [4],
and several heat-stable (HS) serotypes (Penner
serotypes) of C. jejuni are associated with GBS [5].
However, nothing is known about a link between
particular serotypes and the production of cyto-
kines, which could play a role in the pathogenesis
of the disease. As a ﬁrst step towards under-
standing the pathogenesis of GBS, the present
study investigated the in-vitro induction of
cytokines (interleukin (IL)-2sRa, IL-6, interferon
(IFN)-c and IL-10) by several HS serotypes of
C. jejuni.
All C. jejuni strains were isolated from the
stools of hospitalised patients and were identiﬁed
with conventional bacteriological methods. Sero-
typing was performed with a set of 25 antisera
(Campylobacter Antisera ‘Seiken’ Set; Denka Sei-
ken, Tokyo, Japan) based on Penner’s HS sero-
groups. The selection of serotypes included in the
study was based on the number of strains avail-
able in our collection, so that between ﬁve and
seven strains belonging to each serotype could be
used for cytokine induction. Seven serotypes
tested (HS:2, HS:5, HS:19, HS:37, and the com-
plexes HS:1,44, HS:4,13,16,43,50, HS:23,36,53)
have been associated frequently with GBS; ﬁve
serotypes (HS:8, HS:11, HS:15, HS:31, HS:52) have
not yet been associated with GBS; and one
serotype (HS:3) was the only serotype thought
not to be capable of causing GBS [5].
Peripheral blood mononuclear cells (PBMCs)
were obtained with the use of Biocoll separating
solution (Biochrom, Berlin, Germany). Pooled
blood was collected from healthy blood donors.
Isolated cells were suspended in RPMI-1640
medium enriched with glutamate and heat-inac-
tivated fetal calf serum 10% v ⁄ v (Biochrom) at a
ﬁnal concentration of between 5 · 106 and 1 · 107
cells ⁄mL. A single-cell preparation was used for
all the experiments.
In-vitro induction of cytokines in PBMCs by
various C. jejuni strains was performed as des-
cribed previously for Streptococcus mutans [6].
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Cells were incubated at 37C, in a humidiﬁed CO2
5% v ⁄ v chamber, for 4 days. Preliminary kinetic
studies indicated that cytokine levels were near
maximal after 3 days. On day 4, cells were
sedimented by centrifugation at 200 g at 4C,
after which the supernatants were stored at
) 80C until assayed for cytokine levels. Aliquots
were cultured before and after incubation, to
detect any bacterial contamination. Five control
experiments, consisting of PBMC suspensions
without bacteria, were run in parallel. Levels of
IL-2sRa, IL-6, IFN-c and IL-10 in the culture
supernatants were determined with human cyto-
kine enzyme-linked immunosorbent assay (ELI-
SA) kits (Quantikine; R&D Systems Inc.,
Minneapolis, MN, USA). Statistical analysis was
performed with the Stata program v. 7 (University
of California, Los Angeles, CA, USA), with use of
the non-parametric Kruskal–Wallis and Wilcoxon
tests because of the lack of normality.
The concentrations of the four cytokines in the
supernatants of the PBMC suspensions after
induction with different C. jejuni serotypes are
shown in Table 1. Detectable levels were obtained
in every case, but the values differed greatly from
strain to strain. There were no signiﬁcant differ-
ences in the levels of IL-6, IFN-c and IL-10
between the C. jejuni serotypes and the controls,
as calculated with the non-parametric Kruskal–
Wallis test. For IL-2sRa, signiﬁcant differences
(p < 0.0003) were found with the Kruskal–Wallis
test. Pairwise analysis with the non-parametric
Wilcoxon test revealed signiﬁcant differences
(p < 0.05) between HS:3 and the other serotypes
and controls.
In GBS, it is known that IL-6, synthesised
by activated CD4+ cells of the Th2 phenotype,
promotes the production of antibodies against
peripheral nerve sheath myelin components [7].
High IL-6 concentrations have been found in
active GBS, and have been correlated with the
clinical signs of the disease [3,8]. However, no
correlation has been observed between cerebro-
spinal ﬂuid IL-6 levels and other disease varia-
bles, or between cerebrospinal ﬂuid and serum
IL-6 levels [9]. In the present study, IL-6 produc-
tion by induced PBMCs was similar for the
various C. jejuni serotypes tested and did not
differ from the levels in controls.
IFN-c is produced in increased amounts by
activated T-cells in the blood of GBS patients [10],
but no differences in IFN-c plasma levels have
been observed between GBS patients and healthy
individuals [3,11]. Similarly, no in-vitro differ-
ences in IFN-c induction were found between
GBS-triggering or GBS-non-triggering C. jejuni
serotypes and the controls.
With respect to IL-10, no detectable levels have
been found in the serum or cerebrospinal ﬂuid of
GBS patients [12]. In the experimental model used
in the present study, IL-10 showed great intra-
and inter-serotype variation, but no signiﬁcant
correlation could be established.
IL-2 is produced predominantly by CD4+ Th1
cells. The soluble form of the IL-2 receptor
(IL-2sRa) appears in serum, as it is highly
expressed by cells [13]. It has been suggested that
a correlation exists between the IL-2sRa level in
serum and the activity of autoimmune diseases
[14]. In GBS, high levels of IL-2sRa correlate with
disease severity, while low concentrations parallel
clinical improvement, suggesting a role for this
cytokine in the pathogenesis of GBS [9,15].
Increased levels of IL-2 in GBS would enhance
T-cell activation and stimulate B-cells to secrete
autoantibodies and to produce other proinﬂam-
matory cytokines, which may injure the myelin
sheath and ⁄ or Schwann cells. However, increased
induction of IL-2sRa by the GBS-associated or
GBS-non-associated C. jejuni serotypes was not
observed, with the exception of HS:3, which
induced 5–10-fold lower levels of IL-2sRa.
The pathogenesis of GBS, associated with ante-
cedent C. jejuni infection, is based on antibody
cross-reactions between sialylated peripheral
nerve gangliosides and the sialylated lipopoly-
saccharides of C. jejuni [1]. The lipopolysaccharide
Table 1. Cytokine levels induced by different Campylobac-
ter jejuni serotypes (1.5 · 106 CFU ⁄mL) in supernatant
ﬂuids from peripheral blood mononuclear cells (PBMCs)
Serotype
(no. of strains)
Mean ± SD (pg ⁄mL) in 106 PBMC ⁄mL supernatant
IL-2sRa IL-6 IFN-c IL-10
Controls (5) 21.46 ± 10.96 88.30 ± 52.61 41.98 ± 30.80 24.96 ± 28.72
HS:1,44 (6) 13.67 ± 3.33 40.36 ± 39.19 49.27 ± 85.15 42.60 ± 30.70
HS:2 (5) 11.06 ± 2.59 54.18 ± 36.84 50.28 ± 62.92 100.00 ± 172.51
HS:3 (5) 2.17 ± 1.87 22.08 ± 12.81 32.42 ± 53.04 147.40 ± 208.19
HS:4,13,16,43,50 (6) 13.75 ± 9.76 24.02 ± 13.98 104.83 ± 201.81 38.23 ± 54.68
HS:5 (7) 13.91 ± 4.68 41.05 ± 30.66 37.11 ± 37.78 143.22 ± 176.77
HS:8 (5) 17.92 ± 4.77 41.25 ± 23.80 5.15 ± 11.53 23.80 ± 53.21
HS:11 (6) 17.48 ± 6.25 30.38 ± 26.22 23.56 ± 37.51 39.66 ± 54.99
HS:15 (5) 13.94 ± 8.66 30.92 ± 16.43 18.82 ± 33.62 18.40 ± 26.58
HS:19 (5) 18.59 ± 7.27 19.34 ± 6.84 0.26 ± 0.59 49.40 ± 98.11
HS:23,36,53 (6) 15.52 ± 2.59 16.76 ± 13.18 32.19 ± 54.48 94.56 ± 148.55
HS:31 (7) 9.32 ± 4.73 49.63 ± 46.83 42.11 ± 57.71 6.57 ± 17.38
HS:37 (5) 13.05 ± 6.47 12.59 ± 7.46 7.50 ± 16.77 0.232 ± 0.33
HS:52 (6) 13.46 ± 2.74 41.91 ± 43.95 34.24 ± 36.67 24.00 ± 27.45
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of HS:3 is not sialylated [9,16] and it does not
mimic human gangliosides [17], and this serotype
has not been associated with antecedent infection
in GBS patients. Lipopolysaccharide from HS:3
has been used as a negative control in experi-
ments with anti-ganglioside antibodies [18] and,
in the present study, HS:3 failed to induce
signiﬁcant IL-2sRa levels when compared to the
other serotypes. Based on these results, the
question arises as to whether the non-sialylated
structure of HS:3 may be related, via mechanisms
involving IL-2sRa induction, to its inability to
cause GBS. While the absence of molecular mim-
icry with respect to human peripheral nerve
gangliosides could also be responsible, further
studies at the cellular and molecular level are
clearly required to improve our understanding of
the delicate interactions among immunoregula-
tory mechanisms, and to enable the possible
development of new therapeutic approaches.
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